A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab With Darbepoetin Alfa in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 41 patients (estimated)
- Sponsors
- Moffitt Cancer Center
- Collaborators
- Novartis
- Tags
- Erythropoiesis-Stimulating Agent (ESA), Monoclonal Antibody, Red Blood Cell Stimulant
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1493
- NCT Identifier
- NCT04798339
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.